
Current Price | $30.92 | Mkt Cap | $1.3B |
---|---|---|---|
Open | $30.96 | P/E Ratio | 0.00 |
Prev. Close | $30.92 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $30.46 - $32.38 | Volume | 1,082,955 |
52-Wk Range | $13.84 - $62.49 | Avg. Daily Vol. | 1,707,251 |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Current Price | $30.92 | Mkt Cap | $1.3B |
---|---|---|---|
Open | $30.96 | P/E Ratio | 0.00 |
Prev. Close | $30.92 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $30.46 - $32.38 | Volume | 1,082,955 |
52-Wk Range | $13.84 - $62.49 | Avg. Daily Vol. | 1,707,251 |
The best Bull and Bear pitches based on recency and number of recommendations.
The potential for growth in Alzheimer's drugs is huge as our population ages. Cassava has a diagnostic blood test for Alzheimer's in the works and a therapy to treat the disease also in trials.
It has 1 drug candidate for Alzheimer's that is a long-shot for approval. Heavily-shorted stock.
Read the most recent pitches from players about SAVA.
Recs
It has 1 drug candidate for Alzheimer's that is a long-shot for approval. Heavily-shorted stock.
Recs
The potential for growth in Alzheimer's drugs is huge as our population ages. Cassava has a diagnostic blood test for Alzheimer's in the works and a therapy to treat the disease also in trials.
Recs
They just released information of a trial they did with their treatment for Alzheimer's Disease. The results of the trial were positive, patients had an improvement in cognition and behavior. the name of the treatment/drug is Simufilam.
Find the members with the highest scoring picks in SAVA.
medeaschild (79.11) Score: +3,871.78
The Score Leader is the player with the highest score across all their picks in SAVA.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
medeaschild | 79.11 | 12/26/2018 |
![]() |
NS | $0.76 | +3,946.27% | +74.49% | +3,871.78 | 0 Comment | |
foolrrrrrrrrrr | 40.85 | 11/13/2008 |
![]() |
1Y | $37.61 | -18.15% | +399.88% | +418.03 | 0 Comment | |
marcet | 75.10 | 3/2/2009 |
![]() |
3W | $18.82 | +63.51% | +477.83% | +414.32 | 0 Comment | |
SmallCapSurfer2 | 67.14 | 10/13/2016 |
![]() |
3M | $5.32 | +478.57% | +94.07% | +384.50 | 0 Comment | |
Dennyf10 | 65.70 |
|
![]() |
1Y | $35.72 | -13.84% | +361.46% | +375.30 | 0 Comment | |
hackerbobZ | < 20 | 3/23/2009 |
![]() |
5Y | $17.65 | +74.37% | +428.37% | +354.01 | 0 Comment | |
deemonfather42 | < 20 | 7/6/2009 |
![]() |
3W | $22.42 | +37.28% | +362.62% | +325.34 | 0 Comment | |
capptten | < 20 | 12/1/2020 |
![]() |
3M | $7.66 | +301.83% | +12.63% | +289.20 | 1 Comment | |
kozmo66 | < 20 | 9/22/2008 |
![]() |
3M | $38.69 | -20.45% | +239.06% | +259.51 | 0 Comment | |
MARTIJN76 | 93.11 | 10/19/2006 |
![]() |
3M | $35.60 | -13.54% | +220.53% | +234.07 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.